AEterna Zentaris To Present At Upcoming Bio Equity Europe 2006 In Frankfurt, Germany

QUEBEC CITY, May 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. today announced that Prof. Jurgen Engel, Executive Vice President, Global R&D and Chief Operating Officer of the Company, will present a corporate update at Bio Equity Europe 2006 on Tuesday, May 23, 2006, between 11:00 a.m. and 12:15 p.m. (local time), at the Marriott Hotel in Frankfurt, Germany.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a growing global biopharmaceutical company engaged in the discovery, development and marketing of therapies for cancer and endocrine disorders.

AEterna Zentaris also owns 48.29% of the equity of Atrium Biotechnologies Inc. and 64.7% of its voting rights. Atrium is a developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutritional industries.

News releases and additional information are available at www.aeternazentaris.com.

AETERNA ZENTARIS INC. (FORMERLY/ANCIENNEMENT - LES LABORATOIRES AETERNA

CONTACT: Media Relations: Paul Burroughs, (418) 652-8525 ext. 406,paul.burroughs@aeternazentaris.com; Investor Relations: Jenene Thomas,(418) 655-6420 or (908) 996-3154, jenene.thomas@aeternazentaris.com; Torequest a free copy of this organization's annual report, please go tohttp://www.newswire.ca and click on reports@cnw.

Back to news